Next Article in Journal
Dietary Nitrate from Beetroot Juice for Hypertension: A Systematic Review
Next Article in Special Issue
Atrial Fibrillation Predicts Long-Term Outcome after Transcatheter Edge-to-Edge Mitral Valve Repair by MitraClip Implantation
Previous Article in Journal
A Functional Analysis of the Cyclophilin Repertoire in the Protozoan Parasite Trypanosoma Cruzi
Previous Article in Special Issue
Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
Open AccessArticle

Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure—A Single Center Experience

Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany
*
Author to whom correspondence should be addressed.
Biomolecules 2018, 8(4), 133; https://doi.org/10.3390/biom8040133
Received: 4 September 2018 / Revised: 17 October 2018 / Accepted: 29 October 2018 / Published: 2 November 2018
(This article belongs to the Special Issue Biomolecules for Translational Approaches in Cardiology)
Background: Immunoadsorption and intravenous immunoglobulin (IVIG) administration may have beneficial effects in patients with dilated cardiomyopathy with end-stage heart failure. We investigated the effect of immunoadsorption with subsequent IVIG administration on cardiac function and symptoms in patients on optimal medical treatment (OMT) for heart failure (HF) with recent-onset cardiomyopathy during long-term follow-up. Methods: Thirty-five patients with recent-onset of HF symptoms received intensive guideline-recommended medical HF therapy for 5.2 months. Subsequently, all patients received a single cycle of immunoadsorption for five days followed by IVIG administration. During the 29-month follow-up period, New York Heart Association (NYHA) functional class, left ventricular ejection fraction (LVEF) and N-terminal pro brain natriuretic peptide (NT-proBNP) were evaluated. Changes in quality of life (QoL) were assessed using the Minnesota Living with HF Questionnaire. Results: Three months after immunoadsorption, NYHA functional class improved from 2.0 to 1.5 (p < 0.005) and LVEF significantly increased from 27.0% to 39.0% (p < 0.0001). Long-term follow-up of 29 months showed stable NYHA functional class and a further moderate increase in LVEF from 39.0% to 42.0% (p < 0.0001) accompanied by a significant improvement in NT-proBNP and QoL scores. Conclusion: Immunoadsorption followed by IVIG administration further enhances LVEF, HF symptoms, QoL and biomarkers in patients with recent-onset HF on OMT. View Full-Text
Keywords: immunoadsorption; responsiveness to therapy; cardiomyopathy; heart failure immunoadsorption; responsiveness to therapy; cardiomyopathy; heart failure
Show Figures

Figure 1

MDPI and ACS Style

Weinmann, K.; Werner, J.; Koenig, W.; Rottbauer, W.; Walcher, D.; Keßler, M. Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure—A Single Center Experience. Biomolecules 2018, 8, 133.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop